Cetuximab Outperforms Durvalumab in Treatment of Head and Neck Cancers
The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune...
21-Nov-2024 5:10 PM EST
Add to Favorites